Eledon Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.77 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 225.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Details
| Name | Eledon Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 33 |
| Founded | 2004 |
| Ceo | David-Alexandre Gros |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US28617K1016 |
| Cusip | 28617K101 |
| Cik | 1404281 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | Chief Executive Officer and Non Independent Director |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer and Non Independent Director |
| Paul Sean Little | Chief Financial Officer |
| John Herberger | Vice President of Technical Operations |
| Bryan E. Smith J.D. | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer |
| Marina Escudero | Vice President and Head of Clinical Operations |
| Dr. Sepideh Habibi | Vice President and Head of Safety and Pharmacovigilance |
Contact
| Address | 19800 MacArthur Boulevard, Suite 250, Irvine, California 92612, United States |
| Phone | 949 238 8090 |
| Website | https://eledon.com |